FDA approves oral diabetes drug from Novo Nordisk

The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker, which hopes to transform the market by offering patients a noninjectable treatment.

from https://ift.tt/2ABqa4O